<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059406</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 702843-CS2</org_study_id>
    <secondary_id>2019-003505-96</secondary_id>
    <nct_id>NCT04059406</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS TMPRSS6-LRx</brief_title>
  <official_title>A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Patients With Non-Transfusion Dependent β-Thalassemia Intermedia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to evaluate the efficacy, safety, tolerability, pharmacokinetics and
      pharmacodynamics of IONIS TMPRSS6-LRx administered subcutaneously to participants with
      non-transfusion dependent β-Thalassemia Intermedia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, open-label study in up to 45 participants. The duration
      of each participant in the study will be approximately 29 months and will include an
      approximately 2-month screening period, a 24-month treatment period, and a 3-month
      post-treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with a ≥ 1.0 grams per deciliter (g/dL) increase from Baseline in hemoglobin (Hb) at Week 27</measure>
    <time_frame>Baseline and Week 27</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a ≥ 1.5 grams per deciliter (g/dL) increase from Baseline in hemoglobin (Hb) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a ≥ 1.0 milligram of iron per gram of dry weight of liver (mg Fe/g) decrease from Baseline in liver iron concentration (LIC) at Week 53</measure>
    <time_frame>Baseline and Week 53</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Beta Thalassemia Intermedia</condition>
  <arm_group>
    <arm_group_label>IONIS TMPRSS6-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of IONIS TMPRSS6-LRx at multiple dose levels, administered subcutaneously every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS TMPRSS6-LRx</intervention_name>
    <description>IONIS TMPRSS6-LRx administered subcutaneously</description>
    <arm_group_label>IONIS TMPRSS6-LRx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness to comply with study procedures

          -  Clinical diagnosis of Beta-Thalassemia Intermedia with genotypic confirmation

          -  Non-transfusion dependent, as defined by: no more than 6 transfusions in the past
             12-month period, and no transfusions in the 8-week period prior to Day 1

          -  Mean Hb within the range of 6.0-10.0 g/dL, inclusive at Screening

          -  LIC within the range of 3.0-20.0 mg Fe/g dry weight, inclusive

          -  If using chelators, must be on a stable dose for at least 3 months with LIC &gt; 5.0 mg
             Fe/g dry weight and serum ferritin &gt; 300 nanograms per milliliter (ng/mL)

          -  Females must be non-pregnant and non-lactating, and either surgically sterile or
             postmenopausal

          -  Males must be surgically sterile, abstinent or using an acceptable contraceptive
             method

        Exclusion Criteria:

          -  Clinically significant abnormalities in lab values, medical history, or physical
             examination

          -  α-globin gene triplication

          -  Symptomatic splenomegaly

          -  Platelet count &lt; lower limit of normal (LLN) or &gt; 1,000 x 10^9/L

          -  Significant concurrent/recent coagulopathy, history of non-traumatic significant
             bleeding; history of immune thrombocytopenic purpura (ITP); current use of SC
             anti-coagulants; history of thrombotic events, including stroke or DVT

          -  Clinically significant renal, liver or cardiac dysfunction

          -  Uncontrolled hypertension (&gt; 140 mm Hg systolic or &gt; 90 mm Hg diastolic)

          -  Fasting blood glucose &gt; 2.0 × upper limit of normal (ULN)

          -  Inability to have a magnetic resonance imaging (MRI) scan

          -  Known history or positive test for human immunodeficiency virus (HIV), hepatitis C
             (HCV), or hepatitis B (HBV)

          -  Active infection requiring systemic antiviral or antimicrobial therapy

          -  Regular excessive use of alcohol

          -  Recent start of hydroxyurea (6 months prior to Day 1)

          -  Treatment with or recent exposure to another investigational drug, biological agent,
             ASO, small interfering ribonucleic acid (siRNA), or device within 1 month of
             Screening, or 5 half-lives of investigational agent, whichever is longer; or treatment
             with or exposure to:

               -  sotatercept (ACE-011), luspatercept (ACE-536), or ruxolitinib within 4 months of
                  Screening

               -  hematopoietic stimulating agents or any hypoxia-inducible factor prolyl
                  hydroxylase inhibitors within 8 weeks of Day 1

               -  prior bone marrow transplant, stem cell transplant, or gene therapy

          -  Surgery associated with significant blood loss within 4 months of Screening,
             splenectomy within 12 months of Screening, or splenectomy scheduled during treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>1-800-679-4747</phone>
    <email>patients@ionisph.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Koutlimbaneio &amp; Triantafylleio General Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok Noi</city>
        <state>Bankok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thalassaemia</keyword>
  <keyword>Beta Thalassemia</keyword>
  <keyword>IONIS TMPRSS6-LRx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

